Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15635529 | 0.97 | JAK2 (0.46) | JAK2HCAR3OPRK1KMT2ACHEK1 | |
| SCHEMBL3837577 | 0.92 | JAK2 (0.43) | JAK2HCAR3OPRK1KMT2A | |
| SCHEMBL4100544 | 0.87 | HCAR3 (0.38) | JAK2HCAR3OPRK1CHEK1CSNK2A2 | |
| SCHEMBL17110968 | 0.86 | MAPK8 (0.43) | JAK2HCAR3SYK | |
| SCHEMBL870326 | 0.85 | SSTR4 (0.46) | JAK2OPRK1CHEK1CSNK2A2CSNK2B | |
| SCHEMBL871377 | 0.83 | PDGFRB (0.46) | JAK2HCAR3OPRK1 | |
| SCHEMBL871376 | 0.83 | PDGFRB (0.46) | JAK2HCAR3OPRK1 | |
| SCHEMBL15636753 | 0.83 | TRPA1 (0.39) | JAK2HCAR3OPRK1CHEK1 | |
| SCHEMBL4104650 | 0.82 | MAPK1 (0.38) | JAK2HCAR3OPRK1CHEK1 | |
| SCHEMBL12941947 | 0.82 | HCAR3 (0.46) | JAK2HCAR3OPRK1CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2106396-B1 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ALCON RES LTD (US) | 2014-09-24 | — | — | EP | disclosed |
| CN-102532135-A | Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors | ASTRAZENECA AB | 2012-07-04 | — | — | CN | disclosed |
| US-20120077801-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2012-03-29 | — | — | US | disclosed |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | ALCON RESEARCH, LTD. | 2010-08-12 | — | — | US | disclosed |
| CN-101636388-A | Compound 637: pyridopyrimidinediones as PDE4 inhibitors | ASTRAZENECA AB | 2010-01-27 | — | — | CN | disclosed |
| EP-2106396-A2 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | AstraZeneca AB (SE) | 2009-10-07 | — | — | EP | disclosed |
| US-20090124596-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2009-05-14 | — | — | US | disclosed |
| WO-2008084223-A2 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077801-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | JAK2 1299/4885HCAR3 980/4885OPRK1 1482/4885 |
| US-20090124596-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | JAK2 1299/4885HCAR3 980/4885OPRK1 1482/4885 |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | PDE4A, PDE4B, PDE5A | JAK2 1968/4885HCAR3 2479/4885OPRK1 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.